Top Markets
Coin of the day
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
株式のランク #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
株価
$93.80
最終同期: 2025-04-28
時価総額
$2.68B
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Aerovate Therapeutics, Inc. (AVTE)

カテゴリー

Aerovate Therapeutics, Inc.(AVTE)のP/S比率
August 2026 時点のP/S比率 TTM: 0.00
Aerovate Therapeutics, Inc. の最新の財務報告および株価によると、現在のP/S比率(TTM)は 0.00 です。2023 年末時点でのP/S比率は 0.00 でした。
Aerovate Therapeutics, Inc. の P/S 比率の履歴(2020 ~ 2026)
各年末時点のP/S比率
P/S比率 変化
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
同業他社のP/S比率
企業 P/S比率 P/S比率の差
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH